5:19 PM ET
8-K
Licensing Deal
Biohaven Licensing Deal with Ono Pharmaceutical Co., Ltd. Worth $100M
Biohaven granted Ono Pharmaceutical an exclusive license to develop and commercialize its MoDE pan IgG degrader portfolio, including lead candidate BHV-1300, in Japan, South Korea, Taiwan, and ASEAN countries. Biohaven receives an $80 million upfront payment and is eligible for a $20 million milestone payment plus royalties of approximately 20% on net sales in the territory.
- Value
- $100M
- Counterparty
- Ono Pharmaceutical Co., Ltd.